Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients

References

• van Roessel S, Middeldorp S, Cheung YW, et al. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014 Jul;72(6):305–310.
   PubMed Web of Science ®Google Scholar
• Aarab R, van Es J, de Pont AC, et al. Monitoring of unfractionated heparin in critically ill patients. Neth J Med. 2013 Nov;71(9):466–471.
   PubMed Web of Science ®Google Scholar
• Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015 May;16(2):147–153. doi: 10.1177/1751143714564816
   PubMedGoogle Scholar
• Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. [2001 Jun 19];103(24):2994–3018. doi: 10.1161/01.CIR.103.24.2994
   PubMed Web of Science ®Google Scholar
• Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1094–1096. doi: 10.1161/hq0701.093686
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995 Oct;108(4 Suppl):258S–275S. doi: 10.1378/chest.108.4_Supplement.258S
   PubMed Web of Science ®Google Scholar
• Baluwala I, Favaloro EJ, Pasalic L. Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol. 2017 Jul;10(7):595–605. doi: 10.1080/17474086.2017.1345306
   PubMed Web of Science ®Google Scholar
• Chen Y, Phoon PHY, Hwang NC. Heparin resistance during cardiopulmonary bypass in adult cardiac surgery. J Cardiothorac Vasc Anesth. 2022 Nov;36(11):4150–4160. doi: 10.1053/j.jvca.2022.06.021
   PubMed Web of Science ®Google Scholar
• Adams RL, Bird RJ. Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton). 2009 Aug;14(5):462–470. doi: 10.1111/j.1440-1797.2009.01128.x
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen JE, Deykin D, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1992 Oct;102(4 Suppl):337S–351S. doi: 10.1378/chest.102.4_Supplement.337S
   PubMed Web of Science ®Google Scholar
• Dean CL. An overview of heparin monitoring with the anti-Xa assay. Methods Mol Biol. 2023;2663:343–353.
   PubMedGoogle Scholar
• Horton S, Augustin S. Activated clotting time (ACT). Methods Mol Biol. 2013;992:155–167.
   PubMedGoogle Scholar
• Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992 May;22(5):359–374. doi: 10.2165/00003088-199222050-00003
   PubMed Web of Science ®Google Scholar
• Ward RA. Heparinization for routine hemodialysis. Adv Ren Replace Ther. 1995 Oct;2(4):362–370. doi: 10.1016/S1073-4449(12)80034-3
   PubMedGoogle Scholar
• Boneu B, Caranobe C, Sie P. 3 Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol. 1990 Jul;3(3):531–544. doi: 10.1016/S0950-3536(05)80017-4
   PubMedGoogle Scholar
• Morales Castro D, Dresser L, Granton J, et al. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023 Feb;62(2):209–220. doi: 10.1007/s40262-023-01213-x
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498–509. doi: 10.1016/S1473-3099(14)70036-2
   PubMed Web of Science ®Google Scholar
• Zamoner W, de Freitas FM, Garms DS, et al. Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients. Pharmacol Res Perspect. 2016 Dec;4(6):e00280. doi: 10.1002/prp2.280
   PubMed Web of Science ®Google Scholar
• Evans T. Diagnosis and management of sepsis. Clin Med. 2018 Mar;18(2):146–149. doi: 10.7861/clinmedicine.18-2-146
   PubMed Web of Science ®Google Scholar
• Goligher EC, Lawler PR, Jensen TP, et al. Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19. JAMA. [2023 Apr 4];329(13):1066–1077. doi: 10.1001/jama.2023.3651
   PubMed Web of Science ®Google Scholar
• Roberts JA, Taccone FS, Lipman JUP. Understanding PK/PD. Intensive care Med. 2016 Nov;42(11):1797–1800. doi: 10.1007/s00134-015-4032-6
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009 Mar;37(3):840–851; quiz 859. doi: 10.1097/CCM.0b013e3181961bff
   PubMed Web of Science ®Google Scholar
• Perez Ruiz de Garibay A, Kortgen A, Leonhardt J, et al. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit Care. [2022 Sep 26];26(1):289. doi: 10.1186/s13054-022-04163-1
   PubMed Web of Science ®Google Scholar
• Shaikhouni S, Yessayan L. Management of acute kidney injury/renal replacement therapy in the intensive care unit. Surg Clin North Am. 2022 Feb;102(1):181–198. doi: 10.1016/j.suc.2021.09.013
   PubMed Web of Science ®Google Scholar
• Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012 May;81(9):819–825. doi: 10.1038/ki.2011.339
   PubMed Web of Science ®Google Scholar
• Woznica EA, Inglot M, Woznica RK, et al. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018 Apr;27(4):547–551. doi: 10.17219/acem/68363
   PubMed Web of Science ®Google Scholar
• Vilay AM, Churchwell MD, Mueller BA. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care. 2008;12(6):235. doi: 10.1186/cc7093
   PubMed Web of Science ®Google Scholar
• Metkus TS, Lindsley J, Fair L, et al. Quality of heart failure care in the intensive care unit. J Card Fail. 2021 Oct;27(10):1111–1125. doi: 10.1016/j.cardfail.2021.08.001
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jarmuzewska EA. The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence. Br J Clin Pharmacol. 2019 Jan;85(1):20–36. doi: 10.1111/bcp.13760
   PubMed Web of Science ®Google Scholar
• Sette H, Hughes RD, Langley PG, et al. Heparin response and clearance in acute and chronic liver disease. Thromb Haemost. [1985 Oct 30];54(3):591–594. doi: 10.1055/s-0038-1660076
   PubMed Web of Science ®Google Scholar
• Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019 Aug;42(8):774–782. doi: 10.1002/clc.23196
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16. doi: 10.2165/11318140-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kamidani R, Okada H, Kawasaki Y, et al. Impact of augmented renal clearance on anticoagulant therapy in critically ill patients with coronavirus disease 2019: a retrospective cohort study. J Infect Chemother. 2024 Feb;30(2):111–117. doi: 10.1016/j.jiac.2023.09.017
   PubMed Web of Science ®Google Scholar
• Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017 Oct;40(5):189–193. doi: 10.18773/austprescr.2017.053
   PubMed Web of Science ®Google Scholar
• Floroff CK, Palm NM, Steinberg DH, et al. Higher maximum doses and infusion rates compared with standard unfractionated heparin therapy are associated with adequate anticoagulation without increased bleeding in both obese and nonobese patients with cardiovascular indications. Pharmacotherapy. 2017 Apr;37(4):393–400. doi: 10.1002/phar.1904
   PubMed Web of Science ®Google Scholar
• George C, Barras M, Coombes J, et al. Unfractionated heparin dosing in obese patients. Int J Clin Pharm. 2020 Apr;42(2):462–473. doi: 10.1007/s11096-020-01004-5
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004 Sep;126(3 Suppl):188S–203S. doi: 10.1378/chest.126.3_suppl.188S
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87. doi: 10.2165/11318100-000000000-00000
   PubMed Web of Science ®Google Scholar
• Riney JN, Hollands JM, Smith JR, et al. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother. 2010 Jul;44(7–8):1141–1151. doi: 10.1345/aph.1P088
   PubMed Web of Science ®Google Scholar
• Hohner EM, Kruer RM, Gilmore VT, et al. Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults. J Crit Care. 2015 Apr;30(2):395–399. doi: 10.1016/j.jcrc.2014.11.020
   PubMed Web of Science ®Google Scholar
• Tse E, Khurana R, Clarke G, et al. Using anti-Xa level for adjusting intravenous unfractionated heparin infusion in peripartum thromboembolic disease. Obstet Med. 2019 Sep;12(3):146–150. doi: 10.1177/1753495X18772993
   PubMed Web of Science ®Google Scholar
• Avram MJ. Pharmacokinetic studies in pregnancy. Semin Perinatol. 2020 Apr;44(3):151227. doi: 10.1016/j.semperi.2020.151227
   PubMed Web of Science ®Google Scholar
• Raschke RA, Guidry JR, Foley MR. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol. 2000 Nov;96(5):804–806. doi: 10.1016/S0029-7844(00)01053-X
   PubMed Web of Science ®Google Scholar
• Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost. 2002 Jan;87(1):92–97. doi: 10.1055/s-0037-1612949
   PubMed Web of Science ®Google Scholar
• Clark NP, Delate T, Cleary SJ, et al. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy. Thromb Res. 2010 May;125(5):402–405. doi: 10.1016/j.thromres.2009.07.014
   PubMed Web of Science ®Google Scholar
• Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016 Nov;13(11):e1002160. doi: 10.1371/journal.pmed.1002160
   PubMed Web of Science ®Google Scholar
• Rachoin JS, Weisberg LS. Renal replacement therapy in the ICU. Crit Care Med. 2019 May;47(5):715–721. doi: 10.1097/CCM.0000000000003701
   PubMed Web of Science ®Google Scholar
• Brandenburger T, Dimski T, Slowinski T, et al. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017 Sep;31(3):387–401. doi: 10.1016/j.bpa.2017.08.005
   PubMedGoogle Scholar
• Wald R, Beaubien-Souligny W, Chanchlani R, et al. Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury. Intensive care Med. 2022 Oct;48(10):1368–1381. doi: 10.1007/s00134-022-06851-6
   PubMed Web of Science ®Google Scholar
• Musalem P, Pedreros-Rosales C, Muller-Ortiz H. Anticoagulation in renal replacement therapies: Why heparin should be abandoned in critical ill patients? Int Urol Nephrol. [2023 Sep 27];56(4):1383–1393. doi: 10.1007/s11255-023-03805-9
   PubMed Web of Science ®Google Scholar
• Singh S. Anticoagulation during renal replacement therapy. Indian J Crit Care Med. 2020 Apr;24(Suppl 3):S112–S116. doi: 10.5005/jp-journals-10071-23412
   PubMedGoogle Scholar
• Legrand M, Tolwani A. Anticoagulation strategies in continuous renal replacement therapy. Semin Dial. 2021 Nov;34(6):416–422. doi: 10.1111/sdi.12959
   PubMed Web of Science ®Google Scholar
• Morabito S, Guzzo I, Vitaliano E, et al. Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT). G Ital Nefrol. 2006 May;23(Suppl 36):S127–38.
   PubMedGoogle Scholar
• Jamal JA, Mueller BA, Choi GY, et al. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015 May;82(1):92–103. doi: 10.1016/j.diagmicrobio.2015.01.013
   PubMed Web of Science ®Google Scholar
• Hoff BM, Maker JH, Dager WE, et al. Antibiotic dosing for critically Ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update. Ann Pharmacother. 2020 Jan;54(1):43–55. doi: 10.1177/1060028019865873
   PubMed Web of Science ®Google Scholar
• Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001 Jan;119(1):64S–94S. doi: 10.1378/chest.119.1_suppl.64S
   PubMed Web of Science ®Google Scholar
• Olson SR, Murphree CR, Zonies D, et al. Thrombosis and bleeding in extracorporeal membrane oxygenation (ECMO) without anticoagulation: a systematic review. Asaio J. [2021 Mar 1];67(3):290–296. doi: 10.1097/MAT.0000000000001230
   PubMed Web of Science ®Google Scholar
• Chlebowski MM, Baltagi S, Carlson M, et al. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care. [2020 Jan 20];24(1):19. doi: 10.1186/s13054-020-2726-9
   PubMed Web of Science ®Google Scholar
• Sklar MC, Sy E, Lequier L, et al. Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review. Ann Am Thorac Soc. 2016 Dec;13(12):2242–2250. doi: 10.1513/AnnalsATS.201605-364SR
   PubMed Web of Science ®Google Scholar
• McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. Asaio J. 2022 [2022 Mar 1];68(3):303–310. doi: 10.1097/MAT.0000000000001652
   PubMed Web of Science ®Google Scholar
• Shekar K, Fraser JF, Smith MT, et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012 Dec;27(6):741 e9–18. doi: 10.1016/j.jcrc.2012.02.013
   PubMed Web of Science ®Google Scholar
• Durrani J, Malik F, Ali N, et al. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8(3):145–148. doi: 10.1080/20009666.2018.1466599
   PubMed Web of Science ®Google Scholar
• Rodgers GM, Mahajerin A. Antithrombin therapy: current state and future outlook. Clin Appl Thromb Hemost. 2023 Jan;29:10760296231205279. doi: 10.1177/10760296231205279
   Web of Science ®Google Scholar
• Kumar G, Maskey A. Anticoagulation in ECMO patients: an overview. Indian J Thorac Cardiovasc Surg. 2021 Apr;37(Suppl 2):241–247. doi: 10.1007/s12055-021-01176-3
   PubMed Web of Science ®Google Scholar
• Levy JH, Connors JM, Longo DL. Heparin resistance — clinical perspectives and management strategies. N Engl J Med. [2021 Aug 26];385(9):826–832. doi: 10.1056/NEJMra2104091
   PubMed Web of Science ®Google Scholar
• Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 2010 May;149(4):613–619. doi: 10.1111/j.1365-2141.2010.08129.x
   PubMed Web of Science ®Google Scholar
• Levy JH, Sniecinski RM, Maier CL, et al. Finding a common definition of heparin resistance in adult cardiac surgery: communication from the ISTH SSC subcommittee on perioperative and critical care thrombosis and hemostasis. J Thromb Haemost. 2024 Apr;22(4):1249–1257. doi: 10.1016/j.jtha.2024.01.001
   PubMed Web of Science ®Google Scholar
• Levy JH, Sniecinski RM, Rocca B, et al. Defining heparin resistance: communication from the ISTH SSC subcommittee of perioperative and critical care thrombosis and hemostasis. J Thromb Haemost. 2023 Dec;21(12):3649–3657. doi: 10.1016/j.jtha.2023.08.013
   PubMed Web of Science ®Google Scholar
• Levy JH, Frere C, Koster A. Resistance to unfractionated heparin in the ICU: evaluation and management options. Intensive care Med. 2023 Aug;49(8):1005–1007. doi: 10.1007/s00134-023-07103-x
   PubMed Web of Science ®Google Scholar
• Anderson JA, Saenko EL. Heparin resistance. Br J Anaesth. 2002 Apr;88(4):467–469. doi: 10.1093/bja/88.4.467
   PubMed Web of Science ®Google Scholar
• Cirisano FD, Lee S, Greenspoon JS. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. J Reprod Med. 1996 Mar;41(3):191–194.
   PubMed Web of Science ®Google Scholar
• Ng VL. Anticoagulation monitoring. Clin Lab Med. 2009 Jun;29(2):283–304. doi: 10.1016/j.cll.2009.05.003
   PubMed Web of Science ®Google Scholar
• Arepally GM, Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):141–152. doi: 10.1161/ATVBAHA.120.315445
   PubMed Web of Science ®Google Scholar
• Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007 Sep;83(983):575–582. doi: 10.1136/pgmj.2007.059188
   PubMed Web of Science ®Google Scholar
• Zhou P, Yin JX, Tao HL, et al. Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis. Clin Chim Acta. 2020 May;504:73–80. doi: 10.1016/j.cca.2020.02.002
   PubMed Web of Science ®Google Scholar
• Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e495–e530. doi: 10.1378/chest.11-2303
   Web of Science ®Google Scholar
• Crowther M, Cook D, Guyatt G, et al. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. J Crit Care. 2014 Jun;29(3):470 e7–15. doi: 10.1016/j.jcrc.2014.02.004
   PubMed Web of Science ®Google Scholar
• Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. [2012 Nov 15];120(20):4160–4167. doi: 10.1182/blood-2012-07-443051
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. [2018 Nov 27];2(22):3360–3392. doi: 10.1182/bloodadvances.2018024489
   PubMed Web of Science ®Google Scholar
• Hvas AM, Favaloro EJ, Hellfritzsch M. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. Expert Rev Hematol. 2021 Apr;14(4):335–346. doi: 10.1080/17474086.2021.1905512
   PubMed Web of Science ®Google Scholar
• Warnock LB, Huang D. Heparin. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. [1993 Nov 1];119(9):874–881. doi: 10.7326/0003-4819-119-9-199311010-00002
   PubMed Web of Science ®Google Scholar
• Whitman-Purves E, Coons JC, Miller T, et al. Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost. 2018 Mar;24(2):310–316. doi: 10.1177/1076029617741363
   PubMed Web of Science ®Google Scholar
• Dalton H, Martin M, Garcia-Filion P, et al. Activated clotting time in inpatient diagnostic and interventional settings. J Thromb Thrombolysis. 2022 Nov;54(4):660–668. doi: 10.1007/s11239-022-02672-y
   PubMed Web of Science ®Google Scholar
• Chiasakul T, Mullier F, Lecompte T, et al. Laboratory monitoring of heparin anticoagulation in hemodialysis: rationale and strategies. Semin Nephrol. 2024 Jan;43(6):151477. doi: 10.1016/j.semnephrol.2023.151477
   Web of Science ®Google Scholar
• Hong JI, Hwang J, Shin HJ. Satisfactory outcome with low activated clotting time in extracorporeal membrane oxygenation. Rev Cardiovasc Med. [2021 Dec 22];22(4):1589–1594. doi: 10.31083/j.rcm2204164
   PubMed Web of Science ®Google Scholar
• Spinler SA, Wittkowsky AK, Nutescu EA, et al. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother. 2005 Jul;39(7–8):1275–1285. doi: 10.1345/aph.1E524
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Joseph L, et al. Defining optimal activated clotting time for percutaneous coronary intervention: a systematic review and Bayesian meta-regression. Catheter Cardiovasc Interv. [2017 Feb 15];89(3):351–366. doi: 10.1002/ccd.26652
   PubMed Web of Science ®Google Scholar
• Lobato RL, Despotis GJ, Levy JH, et al. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010 Jun;139(6):1665–1666. doi: 10.1016/j.jtcvs.2010.02.038
   PubMed Web of Science ®Google Scholar
• Falter F, Razzaq N, John M, et al. Clinical evaluation of measuring the act during elective cardiac surgery with two different devices. J Extra Corpor Technol. 2018 Mar;50(1):38–43. doi: 10.1051/ject/201850038
   PubMedGoogle Scholar
• Byun JH, Jang IS, Kim JW, et al. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood Res. 2016 Sep;51(3):171–174. doi: 10.5045/br.2016.51.3.171
   PubMedGoogle Scholar
• Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. [1993 Jul 15];119(2):104–109. doi: 10.7326/0003-4819-119-2-199307150-00002
   PubMed Web of Science ®Google Scholar
• Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991 Feb;151(2):333–337. doi: 10.1001/archinte.1991.00400020085018
   PubMedGoogle Scholar
• Swayngim R, Preslaski C, Burlew CC, et al. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis. Thromb Res. 2021 Dec;208:18–25. doi: 10.1016/j.thromres.2021.10.010
   PubMed Web of Science ®Google Scholar
• Delmas C, Jacquemin A, Vardon-Bounes F, et al. Anticoagulation Monitoring Under ECMO support: a comparative study between the activated coagulation time and the anti-xa activity assay. J Intensive Care Med. 2020 Jul;35(7):679–686. doi: 10.1177/0885066618776937
   PubMed Web of Science ®Google Scholar
• Liveris A, Bello RA, Friedmann P, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med. 2014 Feb;15(2):e72–9. doi: 10.1097/PCC.0000000000000028
   PubMed Web of Science ®Google Scholar
• Hedeland Y, Gustafsson CM, Touza Z, et al. Hemolysis interference in 10 coagulation assays on an instrument with viscosity-based, chromogenic, and turbidimetric clot detection. Int J Lab Hematol. 2020 Jun;42(3):341–349. doi: 10.1111/ijlh.13188
   PubMed Web of Science ®Google Scholar
• Khan J, Chandler WL. Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support. Artif Organs. 2019 Sep;43(9):880–887. doi: 10.1111/aor.13467
   PubMed Web of Science ®Google Scholar
• Volod O, Bunch CM, Zackariya N, et al. Viscoelastic hemostatic assays: a primer on legacy and new generation Devices. J Clin Med. [2022 Feb 7];11(3):860. doi: 10.3390/jcm11030860
   PubMed Web of Science ®Google Scholar
• Burton AG, Jandrey KE. Use of thromboelastography in clinical practice. Vet Clin North Am Small Anim Pract. 2020 Nov;50(6):1397–1409. doi: 10.1016/j.cvsm.2020.08.001
   PubMed Web of Science ®Google Scholar
• Hasija S, Kapoor PM. Effect of heparin and bivalirudin on the kinetics of clot formation: Viscoelastic coagulation testing. Ann Card Anaesth. 2017 Jan;20(1):122. doi: 10.4103/0971-9784.197855
   PubMedGoogle Scholar
• Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol. 2017;1646:533–543.
   PubMedGoogle Scholar
• Infanger L, Dibiasi C, Schaden E, et al. Comparison of the new viscoelastic coagulation analyzer ClotPro(R) with ROTEM(R) Delta and Conventional Coagulation Tests in Critically Ill Patients with COVID-19. Front Med. 2021;8:777145. doi: 10.3389/fmed.2021.777145
   Web of Science ®Google Scholar
• Buscher H, Zhang D, Nair P. A pilot, randomised controlled trial of a rotational thromboelastometry-based algorithm to treat bleeding episodes in extracorporeal life support: the TEM protocol in ECLS study (TEMPEST). Crit Care Resusc. 2017 Oct;19(Suppl 1):29–36.
   PubMedGoogle Scholar
• Panigada M, Ei G, Brioni M, et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care. [2018 Jan 16];8(1):7. doi: 10.1186/s13613-017-0352-8
   PubMedGoogle Scholar
• Larkins MC, Thombare A. Point-of-care testing. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• Goble JA, Rocafort PT. Point-of-Care Testing. J Pharm Pract. 2017 Apr;30(2):229–237. doi: 10.1177/0897190015587696
   PubMedGoogle Scholar
• Niederdockl J, Dempfle CE, Schonherr HR, et al. Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors. Int J Lab Hematol. 2016 Aug;38(4):426–434. doi: 10.1111/ijlh.12519
   PubMed Web of Science ®Google Scholar
• Lardinois B, Hardy M, Michaux I, et al. Monitoring of unfractionated heparin therapy in the intensive care unit using a point-of-care aPTT: a comparative, longitudinal observational study with laboratory-based aPTT and anti-xa activity measurement. J Clin Med. [2022 Feb 28];11(5):1338. doi: 10.3390/jcm11051338
   PubMed Web of Science ®Google Scholar
• Karigowda L, Deshpande K, Jones S, et al. The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients. Pathology. 2019 Oct;51(6):628–633. doi: 10.1016/j.pathol.2019.05.002
   PubMed Web of Science ®Google Scholar
• Arachchillage DRJ, Vipond L, Laffan M. Limitations on point care APTT for monitoring of unfractionated heparin in intensive care patients. Thromb Res. 2019 Sep;181:124–126. doi: 10.1016/j.thromres.2019.07.029
   PubMed Web of Science ®Google Scholar
• Douglas AD, Jefferis J, Sharma R, et al. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin. Angiology. 2009 Jun;60(3):358–361. doi: 10.1177/0003319709332958
   PubMed Web of Science ®Google Scholar
• McRae HL, Militello L, Refaai MA. Updates in anticoagulation therapy monitoring. Biomedicines. [2021 Mar 6];9(3):262. doi: 10.3390/biomedicines9030262
   PubMed Web of Science ®Google Scholar
• Hussein HM, Georgiadis AL, Qureshi AI. Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures. AJNR Am J Neuroradiol. 2012 Aug;33(7):1211–1220. doi: 10.3174/ajnr.A2621
   PubMed Web of Science ®Google Scholar
• Vermeiren P, Vandevelde A, Peperstraete H, et al. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay. Int J Lab Hematol. 2022 Aug;44(4):785–795. doi: 10.1111/ijlh.13836
   PubMedGoogle Scholar
• Wu Y, Lu Y, Zhang J. Thrombin generation assay: the present and the future. Blood Coagul Fibrinolysis. [2023 Jan 1];34(1):1–7. doi: 10.1097/MBC.0000000000001170
   PubMed Web of Science ®Google Scholar
• Benoit R, Nougier C, Desmurs-Clavel H, et al. The modification of the thrombin generation assay for the clinical assessment of hypercoagulability in patients receiving heparin therapy. Int J Lab Hematol. 2022 Apr;44(2):371–378. doi: 10.1111/ijlh.13735
   PubMed Web of Science ®Google Scholar
• Binder NB, Depasse F, Mueller J, et al. Clinical use of thrombin generation assays. J Thromb Haemost. 2021 Dec;19(12):2918–2929. doi: 10.1111/jth.15538
   PubMed Web of Science ®Google Scholar
• Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2021 Apr;19(4):892–908. doi: 10.1111/jth.15217
   PubMed Web of Science ®Google Scholar
• Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory. Lab Med. [2017 Nov 8];48(4):295–313. doi: 10.1093/labmed/lmx050
   PubMed Web of Science ®Google Scholar
• Raber MN. Coagulation Tests. In:Walker H, Hall W, and Hurst J, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworth Publishers, a division of Reed Publishing; 1990. p. 741. PMID: 21250108.
   Google Scholar
• Apipongrat D, Police P, Lamool R, et al. Validation of high concentrated thrombin time assay for unfractionated heparin monitoring. J Clin Lab Anal. 2022 Oct;36(10):e24695. doi: 10.1002/jcla.24695
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Marbet GA, Lammle B, et al. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. Am J Clin Pathol. 1980 Jul;74(1):68–73. doi: 10.1093/ajcp/74.1.68
   PubMed Web of Science ®Google Scholar
• Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest. 2010 Jun;137(6):1382–1390. doi: 10.1378/chest.09-0959
   PubMed Web of Science ®Google Scholar
• Malato A, Dentali F, Siragusa S, et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus. 2015 Oct;13(4):559–568. doi: 10.2450/2015.0277-14
   PubMed Web of Science ®Google Scholar
• Neuenfeldt FS, Weigand MA, Fischer D. Coagulopathies in intensive care medicine: balancing act between thrombosis and bleeding. J Clin Med. [2021 Nov 18];10(22):5369. doi: 10.3390/jcm10225369
   PubMed Web of Science ®Google Scholar
• Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care. [2015 Aug 18];19(1):287. doi: 10.1186/s13054-015-1003-9
   PubMedGoogle Scholar
• Ejaz A, Ahmed MM, Tasleem A, et al. Thromboprophylaxis in intensive care unit patients: a literature review. Cureus. [2018 Sep 21];10(9):e3341. doi: 10.7759/cureus.3341
   PubMedGoogle Scholar
• Selby R, Geerts W, Ofosu FA, et al. Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism. Thromb Res. 2009 Jul;124(3):281–287. doi: 10.1016/j.thromres.2008.10.002
   PubMed Web of Science ®Google Scholar
• Prior SM, Cohen MJ, Conroy AS, et al. Correlation between factor (F)xia, FIXa and tissue factor and trauma severity. J Trauma Acute Care Surg. 2017 Jun;82(6):1073–1079. doi: 10.1097/TA.0000000000001449
   PubMed Web of Science ®Google Scholar
• Mi YH, Xu MY. Trauma-induced pulmonary thromboembolism: What’s update? Chin J Traumatol. 2022 Mar;25(2):67–76. doi: 10.1016/j.cjtee.2021.08.003
   PubMed Web of Science ®Google Scholar
• Martini WZ. Coagulation complications following trauma. Mil Med Res. 2016;3(1):35. doi: 10.1186/s40779-016-0105-2
   PubMedGoogle Scholar
• Subat YW, Rayes H, Hanson AC, et al. Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. J Crit Care. 2020 Aug;58:34–40. doi: 10.1016/j.jcrc.2020.04.003
   PubMed Web of Science ®Google Scholar
• Moller MH, Skrifvars MB, Azoulay E. ICM focus on thrombosis and bleeding. Intensive care Med. 2017 Dec;43(12):1910–1911. doi: 10.1007/s00134-017-4966-y
   PubMed Web of Science ®Google Scholar
• Johnston B, Nelson A, Waite AC, et al. Anticoagulation strategies in critical care for the treatment of atrial fibrillation: a protocol for a systematic review and meta-analysis. BMJ Open. [2020 Oct 20];10(10):e037591. doi: 10.1136/bmjopen-2020-037591
   PubMed Web of Science ®Google Scholar
• Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10(4):222. doi: 10.1186/cc4975
   PubMed Web of Science ®Google Scholar
• Lisman T. Bleeding and thrombosis in patients with cirrhosis: what’s new? Hemasphere. 2023 Jun;7(6):e886. doi: 10.1097/HS9.0000000000000886
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, D’Ambrosio R, et al. Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis. Hepatology. [2024 Jan 12]. doi: 10.1097/HEP.0000000000000756
   Web of Science ®Google Scholar
• Sinegre T, Duron C, Lecompte T, et al. Intraindividual variability over time of thrombin generation in patients with cirrhosis. J Thromb Haemost. 2023 Jun;21(6):1441–1452. doi: 10.1016/j.jtha.2023.02.002
   PubMed Web of Science ®Google Scholar
• Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015(1):243–249. doi: 10.1182/asheducation-2015.1.243
   PubMedGoogle Scholar
• Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J. 2008 Apr;84(990):177–181. doi: 10.1136/pgmj.2007.066415
   PubMed Web of Science ®Google Scholar
• Potze W, Arshad F, Adelmeijer J, et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol. 2013 Dec;163(5):666–673. doi: 10.1111/bjh.12593
   PubMed Web of Science ®Google Scholar
• Fuentes A, Gordon-Burroughs S, Hall JB, et al. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis. Ther Drug Monit. 2015 Feb;37(1):40–44. doi: 10.1097/FTD.0000000000000105
   PubMed Web of Science ®Google Scholar
• Potze W, Lisman T. Issues with monitoring of unfractionated heparin in cirrhosis. Ther Drug Monit. 2015 Apr;37(2):279–280. doi: 10.1097/FTD.0000000000000132
   PubMed Web of Science ®Google Scholar
• Anton FI, Rus PA, Hagau N. Monitoring anticoagulation with unfractionated heparin on renal replacement therapy. which is the best aPTT sampling site? J Crit Care Med (Targu Mures). 2020 Jul;6(3):159–166. doi: 10.2478/jccm-2020-0024
   PubMedGoogle Scholar
• Deep A. Anticoagulation strategies in continuous kidney replacement therapy - does one size fit all? Pediatr Nephrol. 2022 Nov;37(11):2525–2529. doi: 10.1007/s00467-022-05567-5
   PubMed Web of Science ®Google Scholar
• Feih JT, Wallskog KE, Rinka JRG, et al. Heparin monitoring with an anti-xa protocol compared to activated clotting time in patients on temporary mechanical circulatory support. Ann Pharmacother. 2022 May;56(5):513–523. doi: 10.1177/10600280211039582
   PubMed Web of Science ®Google Scholar
• Atallah S, Liebl M, Fitousis K, et al. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion. 2014 Sep;29(5):456–461. doi: 10.1177/0267659114524264
   PubMed Web of Science ®Google Scholar
• Kulig CE, Schomer KJ, Black HB, et al. Activated partial thromboplastin time versus anti-factor xa monitoring of heparin anticoagulation in adult venoarterial extracorporeal membrane oxygenation patients. Asaio J. [2021 Apr 1];67(4):411–415. doi: 10.1097/MAT.0000000000001246
   PubMed Web of Science ®Google Scholar
• Figueroa Villalba CA, Brogan TV, Dm M, et al. Conversion from activated clotting time to anti-xa heparin activity assay for heparin monitoring during extracorporeal membrane oxygenation. Crit Care Med. 2020 Dec;48(12):e1179–e1184. doi: 10.1097/CCM.0000000000004615
   PubMed Web of Science ®Google Scholar
• Kostousov V, Nguyen K, Hundalani SG, et al. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med. 2014 Nov;138(11):1503–1506. doi: 10.5858/arpa.2013-0572-OA
   PubMed Web of Science ®Google Scholar
• Mahmoud L, Zullo AR, McKaig D, et al. Concordance between activated partial thromboplastin time and antifactor xa assay for monitoring unfractionated heparin in hospitalized hyperbilirubinemic patients. R I Med J (2013). 2016 Mar 1;99(3):33–37.
   PubMedGoogle Scholar
• Molhoek JE, de Groot PG, Urbanus RT. The Lupus Anticoagulant Paradox. Semin Thromb Hemost. 2018 Jul;44(5):445–452. doi: 10.1055/s-0037-1606190
   PubMed Web of Science ®Google Scholar
• Falconer N, Abdel-Hafez A, Scott IA, et al. Systematic review of machine learning models for personalised dosing of heparin. Br J Clin Pharmacol. 2021 Nov;87(11):4124–4139. doi: 10.1111/bcp.14852
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e24–e43. doi: 10.1378/chest.11-2291
   Web of Science ®Google Scholar
• Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012 Jun;32(6):546–558. doi: 10.1002/j.1875-9114.2011.01049.x
   PubMed Web of Science ®Google Scholar
• Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011 Jul;45(7–8):861–868. doi: 10.1345/aph.1Q161
   PubMed Web of Science ®Google Scholar
• Williams-Norwood T, Caswell M, Milner B, et al. Design and Implementation of an anti-factor Xa heparin monitoring protocol. AACN Adv Crit Care. [2020 Jun 15];31(2):129–137. doi: 10.4037/aacnacc2020132
   PubMed Web of Science ®Google Scholar
• Fruge KS, Lee YR. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring. Am J Health Syst Pharm. [2015 Sep 1];72(17 Suppl 2):S90–7. doi: 10.2146/sp150016
   PubMed Web of Science ®Google Scholar
• Coons JC, Iasella CJ, Thornberg M, et al. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time. Am J Hematol. 2019 Sep;94(9):1015–1019. doi: 10.1002/ajh.25565
   PubMed Web of Science ®Google Scholar
• Wahking RA, Hargreaves RH, Lockwood SM, et al. Comparing anti-factor xa and activated partial thromboplastin levels for monitoring unfractionated heparin. Ann Pharmacother. 2019 Aug;53(8):801–805. doi: 10.1177/1060028019835202
   PubMed Web of Science ®Google Scholar
• Macedo KA, Tatarian P, Eugenio KR. Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin. Ann Pharmacother. 2018 Feb;52(2):154–159. doi: 10.1177/1060028017729481
   PubMed Web of Science ®Google Scholar
• Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm. [2016 Dec 15];73(24):2037–2041. doi: 10.2146/ajhp150596
   PubMed Web of Science ®Google Scholar
• Samuel S, Allison TA, Sharaf S, et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther. 2016 Oct;41(5):499–502. doi: 10.1111/jcpt.12415
   PubMed Web of Science ®Google Scholar